Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established brand medications more affordable for consumers. Beginning today, eligible commercially insured patients may pay as low as $0–$4 on select Viatris medications through GoodRx. Cash-paying consumers, regardless of insurance status, can use GoodRx to access discounted cas.

GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct. As one of Lilly's Employer Connect independent program administrators, GoodRx enables self-insured employers to access Zepbound KwikPen at a set price of $449 across all doses, with the flexibility to further subsidize the cost for employees a.

GoodRx Reports Fourth Quarter and Full Year 2025 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights Revenue of $194.8 million Net income of $5.4 million; Net income margin of 2.8% Adjusted Net Income1 of $29.0 million; Adjusted Net Income Margin1 of 14.9% Adjusted EBITDA1 of $65.0 million; Adjusted EBITD.

GoodRx Expands Into Employer Market With Launch of “GoodRx Employer Direct”

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced the launch of GoodRx Employer Direct. The new offering enables employers to directly lower the cost of high-impact brand medications, including GLP-1s, by applying targeted subsidies to discounted cash prices from pharmaceutical manufacturers. Employers can also deploy branded versions of GoodRx's condition-specific telemedicine solutions, integrating clinical.